Evotec Reports Results of the Annual General Meeting 2026

EQS-News: Evotec SE / Key word(s): AGM/EGM Evotec Reports Results of the Annual General Meeting 2026 11.06.2026 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement.   All agenda items adopted Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board Dieter Weinand appointed Chairman of the Supervisory Board Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board   Hamburg, Germany, June 11, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

All agenda items put to vote were adopted by the Company’s shareholders with the required majority.

Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual General Meeting, the Supervisory Board appointed Dieter Weinand as its Chairman, succeeding Prof. Dr. Iris Löw-Friedrich. In addition, shareholders approved the re-election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board.

Overall, 43.10% of the Company’s registered share capital was represented at the Annual General Meeting.

Further information on the Company’s Annual General Meeting, including the voting results on all agenda items, will be made available shortly on Evotec’s website.

 

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Schreibe Deinen Kommentar